Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Natural killer (NK) cells attack many tumour cell lines, and are thought to have a critical role in anti-tumour immunity; however, the interaction between NK cells and tumour targets is poorly understood. The stimulatory lectin-like NKG2D receptor is expressed by NK cells, activated CD8+ T cells and by activated macrophages in mice. Several distinct cell-surface ligands that are related to class I major histocompatibility complex molecules have been identified, some of which are expressed at high levels by tumour cells but not by normal cells in adults. However, no direct evidence links the expression of these 'induced self' ligands with tumour cell rejection. Here we demonstrate that ectopic expression of the murine NKG2D ligands Rae1beta or H60 in several tumour cell lines results in potent rejection of the tumour cells by syngeneic mice. Rejection is mediated by NK cells and/or CD8+ T cells. The ligand-expressing tumour cells induce potent priming of cytotoxic T cells and sensitization of NK cells in vivo. Mice that are exposed to live or irradiated tumour cells expressing Rae1 or H60 are specifically immune to subsequent challenge with tumour cells that lack NKG2D ligands, suggesting application of the ligands in the design of tumour vaccines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“NKG2D has been implicated in immune surveillance of tumors using transgenic models of spontaneous cancer as well as subcutaneous tumor transfer models (Cerwenka et al., 2001; Diefenbach et al., 2001; Guerra et al., 2008).”
From p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells (2013) · cites this paper as Diefenbach et al., 2001
In the citing paper
“Previous studies from our laboratory demonstrated that transplanted tumor cells expressing NKG2D ligands are rejected by NK cells and, in some cases, T cells (Diefenbach et al., 2000, 2001, 2003)”
From p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells (2013) · cites this paper as Diefenbach et al., 2001
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Activation of NK Cells and T Cells by NKG2D, a Receptor for Stress-Inducible MICA
Bauer, S., Groh, V., Wu, J., Steinle, A., Phillips, J. H., Lanier, L. L., & Spies, T. (1999) · Science · doi:10.1126/science.285.5428.727 · Cited by 2,999
Biology of Natural Killer Cells
Trinchieri, G. (1989) · Advances in Immunology · doi:10.1016/s0065-2776(08)60664-1 · Cited by 2,902
Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V, Hamada, H., Pardoll, D., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,818 · cited 1×
“However, this was not the case with irradiated ligand-negative B16-BL6 tumour cell”
BackgroundInnate Immunity: The Virtues of a Nonclonal System of Recognition
Medzhitov, R., & Janeway, C. A. (1997) · Cell · doi:10.1016/s0092-8674(00)80412-2 · Cited by 2,434
Selective rejection of H–2-deficient lymphoma variants suggests alternative immune defence strategy
Kärre, K., Ljunggren, H. G., Piontek, G., & Kiessling, R. (1986) · Nature · doi:10.1038/319675a0 · Cited by 2,161
Counting Antigen-Specific CD8 T Cells: A Reevaluation of Bystander Activation during Viral Infection
Murali-Krishna, K., Altman, J. D., Suresh, M., Sourdive, D. J. D., Zajac, A. J., Miller, J. D., Slansky, J., & Ahmed, R. (1998) · Immunity · doi:10.1016/s1074-7613(00)80470-7 · Cited by 1,943 · cited 1×
“IFN-γ production was assayed by stimulating CTLs or NK cells with an equal number of target cells for 5–7 h and staining intracellular IFN-γ as describe”
MethodActivating Receptors and Coreceptors Involved in Human Natural Killer Cell-Mediated Cytolysis
Moretta, A., Bottino, C., Vitale, M., Pende, D., Cantoni, C., Mingari, M. C., Biassoni, R., & Moretta, L. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.197 · Cited by 1,778 · cited 1×
“It is unknown whether engagement of NKG2D in NK cells results in direct stimulation or supplies a co-stimulatory signal that acts in conjunction with signals from other stimulatory receptor”
BackgroundDemonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice
Kaplan, D. H., Shankaran, V., Dighe, A. S., Stockert, E., Aguet, M., Old, L. J., & Schreiber, R. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7556 · Cited by 1,465
Cosman, D., Müllberg, J., Sutherland, C. L., Chin, W., Armitage, R., Fanslow, W., Kubin, M., & Chalupny, N. J. (2001) · Immunity · doi:10.1016/s1074-7613(01)00095-4 · Cited by 1,232 · cited 1×
“Several distinct cell-surface ligands that are related to class I major histocompatibility complex molecules have been identifie”
BackgroundRole of Bone Marrow-Derived Cells in Presenting MHC Class I-Restricted Tumor Antigens
Huang, A. Y. C., Golumbek, P., Ahmadzadeh, M., Jaffee, E., Pardoll, D., & Levitsky, H. (1994) · Science · doi:10.1126/science.7513904 · Cited by 1,160
Cited by
Items 601–700 of 1,000
Yokoyama, W. M., & Riley, J. K. (2008) · Reproductive BioMedicine Online · doi:10.1016/s1472-6483(10)60573-1 · Cited by 30
“Thus, the function of NKG2D is generally thought to trigger immune cells due to inflammatory reactions, which lead to stress-induced expression of self-molecules (Diefenbach et al., 2001), resulting in immune control or autoimmunity.”
BackgroundGillard, G. O., Bivas‐Benita, M., Hovav, A., Grandpre, L. E., Panas, M. W., Seaman, M. S., Haynes, B. F., & Letvin, N. L. (2011) · PLoS Pathogens · doi:10.1371/annotation/b29086ef-e08d-444c-8113-18a6dd429a7c · Cited by 27
The Role of Mathematical Models in Immuno-Oncology: Challenges and Future Perspectives
Sancho‐Araiz, A., Sanjuan, V. M., & Trocóniz, I. F. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13071016 · Cited by 30
“839 day−1 None None 3 × 105 B16-BL6 cells [91]/Human [92] Metastatic melanoma Chemotherapy + TIL [93]”
BackgroundInfluentialCho, H.-M., Rosenblatt, J. D., Tolba, K. A., Shin, S. J., Shin, D. S., Calfa, C., Zhang, Y., & Shin, S.-U. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1047 · Cited by 27
“Specifically, NKG2D is expressed on the surface of most NK cells, activated CD8þ ab T cells, antigenspecific CD8þ memory T cells, a subset of gd T cells and on activated macrophages (10, 17).”
BackgroundLoss of type I IFN responsiveness impairs natural killer cell antitumor activity in breast cancer
Zanker, D. J., Owen, K. L., Baschuk, N., Spurling, A., & Parker, B. S. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02857-z · Cited by 29
4-1BB regulates NKG2D costimulation in human cord blood CD8+ T cells
Kim, Y., Han, M., & Broxmeyer, H. E. (2007) · Blood · doi:10.1182/blood-2007-01-069450 · Cited by 29
Chen, G. E., Wu, H., Ma, J., Chadban, S. J., & Sharland, A. F. (2011) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfr234 · Cited by 26
Targeting NKG2D in tumor surveillance
Hayakawa, Y. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2012.681378 · Cited by 26
“Recent evidence clearly implicates that NKG2D recognition plays an important role in tumor immune surveillance and that NKG2D primarily acts to trigger cytotoxicity of immune effector cells [14-17].”
BackgroundInfluentialBrusilovsky, M., Rosental, B., Shemesh, A., Appel, M. Y., & Porgador, A. (2012) · Journal of Immunotoxicology · doi:10.3109/1547691x.2012.675366 · Cited by 25
“As for NK cell effects on adaptive tumor immunity, it was shown that NK cell-mediated elimination of tumor cells induces the subsequent development of tumor-specific T-cell responses to the parental tumor cells (Diefenbach et al., 2001; Kelly et al., 2002).”
BackgroundBitsouni, V., & Tsilidis, V. (2022) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2021.111001 · Cited by 27
“7, are borrowed from [13], in which the authors derived the value of these parameters using data found in [19] and [21].”
BackgroundKumar, A., Dubey, U. S., & Dubey, B. (2024) · Mathematical Biosciences · doi:10.1016/j.mbs.2024.109146 · Cited by 27
Beilke, J. N., Benjamin, J., & Lanier, L. L. (2010) · Blood · doi:10.1182/blood-2010-05-285031 · Cited by 26
Gallaher, J. A., Larripa, K., Renardy, M., Shtylla, B., Tania, N., White, D., Wood, K., Zhu, L., Passey, C., Robbins, M. D. H., et al. (2018) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2018.08.037 · Cited by 26
Zhu, H., Wang, B., Kong, L., An, T., Li, G., Zhou, H., Gong, L., Zhao, Z., Gong, Y., Sun, H., et al. (2019) · Cell chemical biology · doi:10.1016/j.chembiol.2019.04.003 · Cited by 25
Convergent Evolution by Cancer and Viruses in Evading the NKG2D Immune Response
Baugh, R. T., Khalique, H., & Seymour, L. W. (2020) · Cancers · doi:10.3390/cancers12123827 · Cited by 29
Cao, W., & He, W. (2004) · Immunobiology · doi:10.1016/j.imbio.2004.04.008 · Cited by 29
A DNA-based cancer vaccine enhances lymphocyte cross talk by engaging the NKG2D receptor
Zhou, H., Luo, Y., Kaplan, C., Krüger, J. A., Lee, S., Xiang, R., & Reisfeld, R. A. (2005) · Blood · doi:10.1182/blood-2005-10-4231 · Cited by 27
DNA Damage and Tumor Surveillance: One Trigger for Two Pathways
Höglund, P. (2006) · Science s STKE · doi:10.1126/stke.3172006pe2 · Cited by 27
“In mice, the introduction of NKG2D ligands into experimental tumors results in rapid tumor rejection in vivo (16, 17).”
BackgroundZhao, P., Sun, X., Li, H., Liu, Y., Cui, Y., Tian, L., & Cheng, Y. (2022) · Cancers · doi:10.3390/cancers14030457 · Cited by 26
“While mice only have orthologs of human RAET1 genes, including Rae1α/β/γ/δ/ε, MULT1, and H60a/b/c [15].”
Impaired intratumoral natural killer cell function in head and neck carcinoma
Mele, D., Pessino, G., Trisolini, G., Luchena, A., Benazzo, M., Morbini, P., Mantovani, S., Oliviero, B., Mondelli, M. U., & Varchetta, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.997806 · Cited by 24
Expression of the NKG2D ligand UL16 binding protein‐1 (ULBP‐1) on dendritic cells
Schrama, D., Terheyden, P. A. M., Otto, K., Kämmerer, U., Bröcker, E., Lühder, F., Cosman, D. J., Andersen, M. H., & Becker, J. C. (2005) · European Journal of Immunology · doi:10.1002/eji.200535115 · Cited by 24
Natural Killer Cells Require Selectins for Suppression of Subcutaneous Tumors
Sobolev, O., Stern, P., Lacy‐Hulbert, A., & Hynes, R. O. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3126 · Cited by 25
“In addition, as previously reported (12), rejection was NK cell specific because both cell lines gave rise to tumors in GrzA-Ly49Atg mice or in mice treated with the TM-h1 antibody (Fig.”
Jin, F., Lin, H. P., Gao, S., Hu, Z., Zuo, S., Liguang, S., Jin, C., Li, W., & Yang, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.13007 · Cited by 26
Hu, J., Bernatchez, C., Zhang, L., Xia, X., Kleinerman, E. S., Hung, M., Hwu, P., & Li, S. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0234 · Cited by 24
“Expression of NKG2D ligands induced by genetic engineering leads to the rejection of different types of solid tumors and extends survival time in mice (8, 9).”
Burgess, T. L., Amason, J., Rubin, J. S., Duveau, D. Y., Lamy, L., Roberts, D. D., Farrell, C. L., Inglese, J., Thomas, C. J., & Miller, T. W. (2020) · PLoS ONE · doi:10.1371/journal.pone.0226661 · Cited by 24
Dysfunction of natural killer cells in end-stage kidney disease on hemodialysis
Nagai, K. (2021) · Renal Replacement Therapy · doi:10.1186/s41100-021-00324-0 · Cited by 25
Tran, P. D., Christiansen, D., Winterhalter, A. C., Brööks, A. G., Gorrell, M. D., Lilienfeld, B. G., Seebach, J. D., Sandrin, M. S., & Sharland, A. F. (2008) · Xenotransplantation · doi:10.1111/j.1399-3089.2008.00489.x · Cited by 25
“The NKG2D ligands are rarely found in normal adult tissues, but are inducibly expressed, primarily in tissues of epithelial origin, as a result of viral infection, malignant transformation or other conditions of cellular stress [25,32,40].”
BackgroundMa, W., Yu, H. C., Wang, Q., Jin, H., Solheim, J. C., & Labhasetwar, V. D. (2004) · Journal of Clinical Immunology · doi:10.1023/b:joci.0000025451.41948.94 · Cited by 24
A Nonclassical MHC Class I Molecule Restricts CTL-Mediated Rejection of a Syngeneic Melanoma Tumor
Chiang, E. Y., & Stroynowski, I. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.7.4394 · Cited by 29
“Similarly, murine functional homologues of MHC class I chain-related products, retinoic acid early inducible gene product-1 , - , and - and H60, can promote tumor rejection by NK and/or CD8 T cells (34, 35), suggesting that the NKG2D ligands act directly to sensitize NK cells for killing (35) and/or perform costimulat…”
BackgroundNatural killer cells: can they be useful as adoptive immunotherapy for cancer?
Arai, S., & Klingemann, H.-G. (2005) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.5.2.163 · Cited by 24
“provided the first direct evidence in mice of the link between NK cells and CTLs with their common antitumour activation through NKG2D on ligand-expressing tumour cells [13].”
BackgroundTumor-expressed IL-17D recruits NK cells to reject tumors
Saddawi‐Konefka, R., O’Sullivan, T. E., Gross, E. T. E., Washington, A., & Bui, J. D. (2014) · OncoImmunology · doi:10.4161/21624011.2014.954853 · Cited by 24
Alli, R., Savithri, B., Das, S., Varalakshmi, C., Rangaraj, N., & Khar, A. (2004) · European Journal of Immunology · doi:10.1002/eji.200324793 · Cited by 24
Modeling Pancreatic Cancer Dynamics with Immunotherapy
Hu, X., Ke, G., & Jang, S. R. ‐. (2019) · Bulletin of Mathematical Biology · doi:10.1007/s11538-019-00591-3 · Cited by 23
Type 1 Innate Lymphoid Cells Limit the Antitumoral Immune Response
Vienne, M., Etiennot, M., Escalière, B., Galluso, J., Spinelli, L., Guia, S., Fenis, A., Vivier, É., & Kerdiles, Y. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.768989 · Cited by 23
Impaired tumor rejection by memory CD8 T cells in mice with NKG2D dysfunction
Andre, M. C., Sigurdardottir, D., Kuttruff, S., Pömmerl, B., Handgretinger, R., Rammensee, H., & Steinle, A. (2011) · International Journal of Cancer · doi:10.1002/ijc.26191 · Cited by 23
“Immunization with NKG2DL-expressing tumor cells was also shown to induce a specific CD8 T cell memory to parental NKG2DL-negative tumor cells.(19) Although this work demonstrated that NKG2D stimulates tumor immunity in the course of primary CD8 T cell responses, the significance of NKG2D for memory CD8 T cell response…”
BackgroundTheoretical Modeling Techniques and Their Impact on Tumor Immunology
Woelke, A. L., Murgueitio, M. S., & Preißner, R. (2010) · Journal of Immunology Research · doi:10.1155/2010/271794 · Cited by 25
“parameters modified from [27], parameters originally obtained from a published mouse study [28].”
Modeling Tumor–Immune Dynamics
de Pillis, L. G., & Radunskaya, A. (2014) · Springer proceedings in mathematics & statistics · doi:10.1007/978-1-4939-1793-8_4 · Cited by 23
“The data we show are from Diefenbach[24] experiments in which groups of immuno-compromised mice were challenged with increasing levels of B16-BL6 (a melanoma cell line).”
BackgroundMethodInfluentialHave Cells Harboring the HIV Reservoir Been Immunoedited?
Huang, S.-H., McCann, C. D., Mota, T. M., Wang, C., Lipkin, S. M., & Jones, R. B. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01842 · Cited by 24
Abdool, K., Cretney, E., Brooks, A. D., Kelly, J. M., Swann, J. B., Shanker, A., Bere, E. W., Yokoyama, W. M., Ortaldo, J. R., Smyth, M. J., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.4.2575 · Cited by 23
“Furthermore, a number of studies have indicated that recognition by NK cells of NKG2DL on tumor cells can limit tumor development in vivo (13, 16), and that NKG2D signaling predominantly engaged the perforin-mediated effector pathway (19).”
BackgroundImmunomodulatory Effects of Radiofrequency Ablation in a Breast Cancer Model
Todorova, V. K., Klimberg, V. S., Hennings, L. J., Kieber‐Emmons, T., & Pashov, A. D. (2010) · Immunological Investigations · doi:10.3109/08820130903428291 · Cited by 23
“As a part of the innate immune system NK cell–mediated immunity is considered the first defense against tumor cells by causing lysis (Diefenbach et al., 2001; Kelly et al., 2002).”
BackgroundMulrooney, T. J., Posch, P. E., & Hurley, C. K. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.0213093 · Cited by 23
“Expression levels of the NKG2D ligands, MICA/B, Rae-1 and ULBP proteins, have also been correlated with NK cell responses against malignancies [110].”
BackgroundA Truncated Human NKG2D Splice Isoform Negatively Regulates NKG2D-Mediated Function
Karimi, M. A., Aguilar, O. A., Zou, B.-X., Bachmann, M. H., Carlyle, J. R., Baldwin, C. L., & Kambayashi, T. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400920 · Cited by 22
Teferedegne, B., Murata, H., Quiñones, M., Peden, K., & Lewis, A. M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0014416 · Cited by 24
“Furthermore, it was found that NKG2D-mediated tumor rejection can be effective at early stages of tumor growth [49,51,52,53].”
BackgroundPractical considerations for chimeric antigen receptor design and delivery
Oldham, R. A. A., & Medin, J. A. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1339687 · Cited by 22
Luo, X., Wang, Y., Shen, A., Deng, H., & Ye, M. (2019) · BMC Medical Genetics · doi:10.1186/s12881-019-0871-2 · Cited by 22
“MICA protein is a ligand of the NK cell surface activating receptor, NKG2D, which can effectively mediate NK cell killing of tumor cells by binding activation proteins [11]; however, many MICA-positive tumors release soluble MICA (sMICA) into the serum, which inhibits NK cell function [12].”
BackgroundDynamics of a mathematical model of cancer cells with chemotherapy
Lestari, D., Sari, E. R., & Arifah, H. (2019) · Journal of Physics Conference Series · doi:10.1088/1742-6596/1320/1/012026 · Cited by 22
Dhar, P., Basher, F., Ji, Z., Huang, L., Qin, S., Wainwright, D. A., Robinson, J. W., Hagler, S. B., Zhou, J., Mackay, S., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-02440-3 · Cited by 23
Physiological roles of murine DAP10 adapter protein in tumor immunity and autoimmunity
Hyka‐Nouspikel, N., & Phillips, J. H. (2006) · Immunological Reviews · doi:10.1111/j.1600-065x.2006.00456.x · Cited by 23
“NKG2D ligands are required for rejection, as tumors expressing intermediate or low levels were not rejected (27).”
BackgroundKhajanchi, S., Mondal, J., & Tiwari, P. K. (2023) · Journal of Biological Systems · doi:10.1142/s0218339023500171 · Cited by 21
Lutz, S., Klausz, K., Albici, A.-M., Ebinger, L., Sellmer, L., Teipel, H., Frenzel, A., Langner, A., Winterberg, D., Krohn, S., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1227572 · Cited by 22
Nazari, M., Ghaffari, A., & Arab, F. (2014) · Journal of Biological Systems · doi:10.1142/s0218339015500011 · Cited by 21
Natural Killer Cells in the Development of Asthma
Mathias, C. B. (2014) · Current Allergy and Asthma Reports · doi:10.1007/s11882-014-0500-2 · Cited by 27
Cytotoxic Function of Umbilical Cord Blood Natural Killer Cells: Relevance to Adoptive Immunotherapy
Lin, S., & Kuo, M. (2011) · Pediatric Hematology and Oncology · doi:10.3109/08880018.2011.613092 · Cited by 21
Tumor-derived CSF-1 induces the NKG2D ligand RAE-1δ on tumor-infiltrating macrophages
Thompson, T. W., Jackson, B. T., Li, P. J., Wang, J., Kim, A. B., Huang, K. T. H., Zhang, L., & Raulet, D. H. (2018) · eLife · doi:10.7554/elife.32919 · Cited by 21
“Collectively, data here and in previous studies (Diefenbach et al., 2001; Guerra et al., 2008; Thompson et al., 2017) revealed multiple roles of RAE-1 molecules on macrophages, tumor cells, endothelial and other cells.”
ResultSelf-citationKim, Y.-H., Born, C., Bléry, M., & Steinle, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00960 · Cited by 22
“Hence, following the excitement created by early tumor rejection studies in mice (24, 25), subsequent reports on various NKG2D immune escape mechanisms in human cancer dampened this enthusiasm to some extent.”
BackgroundInfluentialMehdizadeh, R., Shariatpanahi, S. P., Goliaei, B., Peyvandi, S., & Rüegg, C. (2021) · Cancers · doi:10.3390/cancers13020245 · Cited by 23
“The study concluded the activation of NK cells and CD8+ T cells, with tumor transduced with NKG2D ligand, lowers tumor growth incidence, and stimulates protective immunity to tumor challenge with ligand-negative tumor cells [88].”
BackgroundExpression of NTRK1/TrkA affects immunogenicity of neuroblastoma cells
Pajtler, K. W., Rebmann, V., Lindemann, M., Schulte, J. H., Schulte, S., Stauder, M., Leuschner, I., Schmid, K., Koehl, U., Schramm, A. R., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.28096 · Cited by 21
“NK cells expressing high NKG2D levels, especially following IL-2 stimulation, have previously been reported to lyse MHC class I-positive target cells.(5,50) Although TrkA-expressing neuroblastoma cells express high NKG2D ligand levels, inhibitory signals mediated by MHC class I expression appear to override the effect…”
BackgroundWagner, A. K., Wickström, S. L., Tallerico, R., Salam, S., Lakshmikanth, T., Brauner, H., Höglund, P., Carbone, E., Johansson, M. H., & Kärre, K. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0001 · Cited by 27
“Previous studies support that high expression of activating ligands, like Rae1g , can override MHC class I–dependent inhibition (32, 37, 38).”
BackgroundResultIn vivo immunogenetics: from MIC to RAET1 loci
Radosavljevic, M., & Bahram, S. (2003) · Immunogenetics · doi:10.1007/s00251-003-0546-0 · Cited by 24
“This has been clearly highlighted in several recent manuscripts where expression of RAE1/H60 class-I-like molecules is necessary and sufficient in order to induce rejection of the hosting tumour (Cerwenka et al. 2001; Diefenbach et al. 2001; Girardi et al. 2001).”
BackgroundA mathematical model with piecewise constant arguments of colorectal cancer with chemo-immunotherapy
Bozkurt, F., Yousef, A., Bilgil, H., & Bǎleanu, D. (2023) · Chaos Solitons & Fractals · doi:10.1016/j.chaos.2023.113207 · Cited by 20
Basher, F., Jeng, E. K., Wong, H. C., & Wu, J. D. (2015) · Oncotarget · doi:10.18632/oncotarget.6416 · Cited by 24
“Ectopic expression of NKG2D ligands results in effective tumor rejection mediated by NK cells, and in some cases primed cytotoxic T cells [5, 6].”
Xie, W., Liu, F., Wang, Y., Ren, X., Wang, T., Chen, Z., Tang, M., Sun, F., Li, Z., Wang, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7501 · Cited by 20
“In addition to FcγRIIIa, NK cells express a variety of activating receptors, among which NKG2D was shown to play an important role in tumor cell rejection and tumor immunosurveillance [19-21].”
BackgroundLawrence, D. W., Willard, P. A., Cochran, A. M., Matchett, E. C., & Kornbluth, J. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.573372 · Cited by 21
“These cells are MHC class I negative and are killed exclusively by NK cells (Kim et al., 2000; Cerwenka et al., 2001; Diefenbach et al., 2001).”
BackgroundGotru, S. K., Gil‐Pulido, J., Beyersdorf, N., Diefenbach, A., Becker, I. C., Vögtle, T., Remer, K. A., Chubanov, V., Gudermann, T. W., Hermanns, H. M., et al. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701467 · Cited by 20
“NK cell–killing assays were performed using 13 10(4) CFDA-SE–labeled (5 mM; Life Technologies) RMA, RMA-H60, or RMARae1b cells (7) per well (96-well V-bottom plate), together with decreasing amounts of activated NK cells from Wt or Magt1 mice.”
MethodSelf-citationdel Toro‐Arreola, S., Arreygue-Garcia, N., Aguilar‐Lemarroy, A., Arregui, A. C., Jiménez-Pérez, M. I., Haramati, J., Barros‐Núñez, P., González‐Ramella, O., Toro‐Arreola, A. D., Ortiz‐Lazareno, P. C., et al. (2011) · Cancer Cell International · doi:10.1186/1475-2867-11-15 · Cited by 19
“[41-43].”
Elaraby, E., Malek, A. I., Abdullah, H. W., Elemam, N. M., Saber-Ayad, M. M., & Talaat, I. M. (2021) · Journal of Immunology Research · doi:10.1155/2021/9972927 · Cited by 21
Kopp, R., Glas, J., Lau‐Werner, U., Albert, E. D., & Weiss, E. H. (2009) · Journal of Clinical Immunology · doi:10.1007/s10875-009-9288-6 · Cited by 19
“The major histocompatibility complex class I chain related A (MICA) and MICB molecules are ligands of NKG2D receptors on natural killer (NK) cells, gamma/delta T cells, NKT cells, and CD8aß T cells, and mediate antitumor immune responses by stimulating innate and adaptive immune surveillance [1–3].”
BackgroundPahl, J. H. W., Ruslan, S. E. N., Kwappenberg, K. M. C., Dam, M. M. V. O.-T., van Tol, M. J. D., Lankester, A. C., & Schilham, M. W. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1406-x · Cited by 20
Humanized Immune System (HIS) Mice as a Tool to Study Human NK Cell Development
Huntington, N. D., & Santo, J. P. D. (2008) · Current topics in microbiology and immunology · doi:10.1007/978-3-540-75647-7_7 · Cited by 20
Russell, P. S., Chase, C. M., Madsen, J. C., Hirohashi, T., Cornell, L. D., Sproule, T. J., Colvin, R. B., & Roopenian, D. C. (2011) · Transplantation · doi:10.1097/tp.0b013e3182122f82 · Cited by 19
“Moreover, the native H60 glycoprotein is a stimulatory ligand for the NKG2D receptor expressed by natural killer cells (13) and may also act as a costimulatory ligand for CD8 T cells (14).”
BackgroundSadrolvaezin, A., Pezhman, A., Zare, I., Nasab, S. Z., Chamani, S., Naghizadeh, A., & Mostafavi, E. (2023) · MedComm · doi:10.1002/mco2.386 · Cited by 20
“36,75,76 Likewise, NKG2D receptors were neutralized by the administration of anti-NKG2D mAb, resulting in significantly reduced ear swelling by Pd 36 (Figure 4).”
BackgroundXu, H., Zhu, X., & Chen, J. (2015) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s96869 · Cited by 18
Jacquelot, N., Seillet, C., Souza-Fonseca-Guimarães, F., Sacher, A. G., Belz, G. T., & Ohashi, P. S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22169044 · Cited by 19
NK cells from pleural effusions are potent antitumor effector cells
Terme, M., Fridman, W. H., & Tartour, É. (2013) · European Journal of Immunology · doi:10.1002/eji.201243264 · Cited by 18
DNA damage response and development of targeted cancer treatments
Gasser, S. (2007) · Annals of Medicine · doi:10.1080/07853890701436773 · Cited by 18
“In some cases long-lasting T cell-mediated immunity against the tumor cells was observed (17,18).”
BackgroundGenetic instability as a driver for immune surveillance
Aguadé‐Gorgorió, G., & Solé, R. V. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0795-6 · Cited by 21
“Tumor size has been shown to be associated with response to immunotherapies [52], but several scenarios, from surveillance to evasion, are known to occur [31, 53, 54].”
BackgroundArming cytotoxic lymphocytes for cancer immunotherapy by means of the NKG2D/NKG2D-ligand system
Lazarova, M., Wels, W. S., & Steinle, A. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1803273 · Cited by 18
A role for the MHC class I‐like Mill molecules in nutrient metabolism and wound healing
Rabinovich, B. A., Ketchem, R. R., Wolfson, M. F., Goldstein, L. C., Skelly, M., & Cosman, D. J. (2008) · Immunology and Cell Biology · doi:10.1038/icb.2008.41 · Cited by 18
Akbulut, H., Tang, Y., AKBULUT, K. G., Maynard, J., Zhang, L., & Deisseroth, A. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0049 · Cited by 18
Ingelshed, K., Melssen, M. M., Kannan, P., Chandramohan, A., Partridge, A. W., Jiang, L., Wermeling, F., Lane, D. P., Nestor, M., & Spiegelberg, D. (2024) · iScience · doi:10.1016/j.isci.2024.109862 · Cited by 17
Zhang, H., Hardamon, C. R., Sagoe, B., Ngolab, J., & Bui, J. D. (2010) · Molecular Immunology · doi:10.1016/j.molimm.2010.10.015 · Cited by 19
“H60a is induced during carcinogenesis (Girardi et al., 2001), and overexpression of H60a on tumor cells is sufficient to mediate tumor rejection by NK cells and prime adaptive immunity (Diefenbach et al., 2001).”
BackgroundPicardi, A., Mengarelli, A., Marino, M., Gallo, E., Benevolo, M., Pescarmona, E. O., Cocco, R., Fraioli, R., Tremante, E., Petti, M. C., et al. (2015) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-015-0213-y · Cited by 18
“NKG2D ligands signal cellular stress in the un-manipulated host and, like HLA-E, they are overexpressed in tumor cells [7–11].”
BackgroundCharacteristics of Peripheral Immune Function in Reproductive Females with Uterine Leiomyoma
Liu, Z.-Q., Lu, M.-Y., Sun, R., Yin, Z., Liu, B., & Wu, Y. (2019) · Journal of Oncology · doi:10.1155/2019/5935640 · Cited by 19
Kandell, W. M., Donatelli, S. S., Trinh, T. L., Calescibetta, A. R., So, T., Tu, N., Gilvary, D. L., Chen, X., Cheng, P., Adams, W. A., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0225820 · Cited by 17
“A robust NK cell response in cancer patients correlates with a positive prognosis [2, 3], and these clinical data translate to animal studies showing that NK cell depletion or inactivation increases tumor burden and worsens prognosis [4, 5].”
BackgroundArina, A., Murillo, O., Hervás‐Stubbs, S., Azpilikueta, A., Dubrot, J., Tirapu, I., Huarte, E., Alfaro, C., Perez‐Gracia, J. L., González‐Aseguinolaza, G., et al. (2007) · International Journal of Cancer · doi:10.1002/ijc.22795 · Cited by 19
“or Rae1 to experimental tumors leads to tumor regression and effective vaccination against untransfected variants.(19) Upon”
BackgroundSelf-citationComplementary activation of peripheral natural killer cell immunity in nasopharyngeal carcinoma
Zheng, Y., Cao, K., Ng, S. P., Chua, D. T. T., Sham, J. S. T., Kwong, D. L. �., Ng, M. H., Lu, L., & Zheng, B. (2006) · Cancer Science · doi:10.1111/j.1349-7006.2006.00252.x · Cited by 17
Induction of human NK cell-mediated cytotoxicity by CD40 triggering on antigen presenting cells
Sartorius, R., D’Apice, L., Barba, P., Guardiola, J., Santoni, A., Velotti, F., & Berardinis, P. D. (2003) · Cellular Immunology · doi:10.1016/s0008-8749(03)00060-1 · Cited by 17
Zwirner, N. W., Fuertes, M. B., Girart, M. V., Domaica, C. I., & Rossi, L. E. (2006) · Cited by 20
Molecular cloning and characterization of a porcine UL16 binding protein (ULBP)-like cDNA
García-Borges, C. N., Phanavanh, B., SARASWATI, S., Dennis, R. A., & Crew, M. D. (2004) · Molecular Immunology · doi:10.1016/j.molimm.2004.09.020 · Cited by 17
“Both of these proteins have been shown to interact with the mouse NKG2D receptor (Cerwenka et al., 2000; Diefenbach et al., 2001).”
BackgroundKellner, C., Lutz, S., Oberg, H., Wesch, D., Otte, A., Diemer, K. J., Wilcken, H., Bauerschlag, D., Glüer, C., Wichmann, C. W., et al. (2021) · Biological Chemistry · doi:10.1515/hsz-2021-0229 · Cited by 17
“Experiments in mice demonstrated that ectopically expressed or antibodydelivered NKG2D ligands triggered T cell tumor immunity inmice (Cho et al. 2010; Diefenbach et al. 2001).”
BackgroundJiang, B., Wu, X., Li, X., Yang, X., Zhou, Y., Yan, H., Wei, A., & Yan, W. (2014) · Cellular Immunology · doi:10.1016/j.cellimm.2014.04.011 · Cited by 18
Redirecting NK cells mediated tumor cell lysis by a new recombinant bifunctional protein
Germain, C., Campigna, E., Salhi, I., Morisseau, S., Navarro‐Teulon, I., Mach, J. P., Pèlegrin, A., & Robert, B. (2008) · Protein Engineering Design and Selection · doi:10.1093/protein/gzn047 · Cited by 18
“It has also been demonstrated in vivo that transfected murine tumor cells expressing Rae1 or H60 are rejected by NK cells, while parental tumor cells critically grow, and that rejection is associated with T cell response priming (Diefenbach et al., 2001).”
BackgroundYong, C. S. M., John, L. B., Devaud, C., Prince, M. H., Johnstone, R. W., Trapani, J. A., Darcy, P. K., & Kershaw, M. H. (2016) · Oncotarget · doi:10.18632/oncotarget.9149 · Cited by 16
“Previous studies have indicated the eradication of intraperitoneal RMA tumor challenges are facilitated through the combined efforts of CD8+ T cells and NK cells [34].”
BackgroundXu, X., Rao, G., & Li, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.11042 · Cited by 16
“In support of this notion, ectopic expression of the murine NKG2D ligands Rae1β or H60 in tumor cell lines results in potent rejection of the tumor cells [51]; Inhibition of XOR activity by allopurinol blocks tumor rejection in a syngeneic mouse model [35].”
BackgroundAlbumin-Based Nitric Oxide Traffic System for the Treatment of Intractable Cancers
Ishima, Y. (2017) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b16-00867 · Cited by 16
NKG2D‐ligands: Putting everything under the same umbrella can be misleading
Campos‐Silva, C., Kramer, M. K., & Valés‐Gómez, M. (2018) · HLA · doi:10.1111/tan.13246 · Cited by 18
“In vivo experiments of tumour rejection through activation of murine NK cells and, in some cases CD8 T cells, confirmed the importance of NKG2Ddependent recognition in tumour immune clearance.(38,84,85) The role of the receptor was further demonstrated a few years later, when NKG2D deficiency was shown to impair immun…”
BackgroundNKG2D signaling regulates IL-17A-producing γδT cells in mice to promote cancer progression
Curio, S., Edwards, S. C., Suzuki, T., McGovern, J. L., Triulzi, C., Yoshida, N., Jonsson, G., Glauner, T. A., Rami, D., Wiesheu, R., et al. (2022) · Discovery Immunology · doi:10.1093/discim/kyac002 · Cited by 16
IFN-gamma suspends the killing license of anti-tumor CTLs
Lukacher, A. E. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0217209 · Cited by 16
Lee, D. H., Nam, J. Y., Chang, Y. W., Cho, H., Kang, S. H., Cho, Y. Y., Cho, E. J., Lee, J., Yu, S. J., Kim, Y. J., et al. (2017) · Cancer Biology & Therapy · doi:10.1080/15384047.2016.1276132 · Cited by 15
“The observed NKG2D-mediated activation of cytotoxic lymphocytes critically relies on NKG2D ligand expression levels at the tumor cell surface.(18) Among NKG2D ligands, MIC-A and MIC-B are constitutively expressed at low levels compared with transcript levels of a housekeeping gene in the HCC cell line.”
BackgroundCharacterization of human natural killer cells for therapeutic use
Wagner, A. K., Alici, E., & Lowdell, M. W. (2019) · Cytotherapy · doi:10.1016/j.jcyt.2018.11.001 · Cited by 18
Metadata
- Authors
- Diefenbach, A., Jensen, E. R., Jamieson, A. M., & Raulet, D. H.
- Affiliations
- University of California, Berkeley (US)
- Corresponding author
- Raulet, David H.
- Venue
- Nature
- Published
- 2001-09-13
- Volume
- 413
- Issue
- 6852
- Pages
- 165-171
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3900321
- OpenAlex
- W1595098530
- Cited by
- 1,083
- References
- 30
- Citations by year
- 2026: 17 · 2025: 28 · 2024: 26 · 2023: 38 · 2022: 28 · 2021: 43 · 2020: 48 · 2019: 37 · 2018: 38 · 2017: 32 · 2016: 34 · 2015: 53 · 2014: 42 · 2013: 48 · 2012: 42
- FWCI
- 15.26
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Canadian Institutes of Health Research
- National Institute of Allergy and Infectious Diseases (R01AI039642)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- NKG2D, Rae1, NKG2D ligands, natural killer cells, tumour immunity, tumor rejection, CD8+ T cells, cancer vaccines, MHC class I
- MeSH terms
- Animals, Cytotoxicity, Immunologic, Immunity, Killer Cells, Natural, Ligands, Membrane Proteins, Mice, Inbred C57BL, Neoplasms, Receptors, Immunologic, Recombinant Proteins, T-Lymphocytes, Cytotoxic, Tumor Cells, Cultured, Minor Histocompatibility Antigens, CD8-Positive T-Lymphocytes, Mice, Receptors, Natural Killer Cell, NK Cell Lectin-Like Receptor Subfamily K
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.